Genmab A/S at Citi Global Healthcare Conference Transcript
Welcome to the next session. So we're sticking with a -- we've got a European pharma afternoon. In fact, pharma biotech afternoon. So we have with us today Genmab, and Anthony Pagano, who's the CFO.
Antony, I don't know if you wanted to make some sort of opening remarks. There's been obviously a lot going on for Genmab in the last 6-, 12 months. Maybe just run through some key points, and then we'll get into some Q&A.
/- -
Yeah. Thanks, Graham, and again, thanks for having us at the conference back here. Again, it's a pleasure to be here and have a chance to engage with all of our investors.
As we start to get in the process of exiting 2025, I find it really useful to reflect on the progress that we've made here at Genmab during the course of the year, and I think it's really interesting to kind of tell the story through the lens of three of our late stage programs
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
